Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.8550 (-2.67%) ($11.8550 - $11.8550) on Mon. Feb. 22, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.03% (three month average) | RSI | 18 | Latest Price | $11.8550(-2.67%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -21.6% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(58%) IWO(53%) XBI(52%) IWM(50%) IWC(48%) | Factors Impacting FOLD price | FOLD will decline at least -2.515% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-12%) UNG(-6%) IGOV(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.515% (StdDev 5.03%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-18.13(-252.93%) | Resistance Level | $17.18 | 5 Day Moving Average | $12.03(-1.45%) | 10 Day Moving Average | $14.81(-19.95%) | 20 Day Moving Average | $17.18(-31%) | To recent high | -52.4% | To recent low | 0% | Market Cap | $3.061b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |